Clinical Evidence Library

Category: Company News

Rhythm Express Founders Honored with Ernst & Young (EY) Heartland 2026 Entrepreneur Of The Year® Award

Over the past decade, the Brockways have transformed ideas into industry-leading solutions which are reshaping cardiovascular and remote patient monitoring.

Ghost patients: why traditional Holter monitoring leaves physicians — and patients — waiting

Traditional extended Holter monitoring can delay arrhythmia diagnosis by weeks. Learn how near real-time cardiac monitoring eliminates blind spots in

Rhythm Express Fact Sheet: Business Models and Benefits

Discover the features and benefits of RX-1 mini, Rhythm Access Portal, ECG reports, and multiple business models.

Rhythm Express Named by Inc. Magazine as One of the Fastest Growing Private Firms in America – AGAIN!

VivaQuant, Inc. d.b.a. Rhythm Express, a leader in remote cardiac monitoring and digital health solutions, has been recognized as one

Once Again, VivaQuant Recognized by Inc. Magazine as One of the Fastest Growing Private Companies in America

VivaQuant, a digital health company providing remote cardiac arrhythmia monitoring services under its Rhythm Express brand, is pleased to announce

VivaQuant Recognized by Inc. Magazine as One of the Fastest Growing Private Companies in America

St. Paul, Minnesota, August 2023 VivaQuant, a digital health company providing remote cardiac arrhythmia monitoring services under its Rhythm Express

Minneapolis Star Tribune: VivaQuant is making an intriguing bet on equity crowdfunding

VivaQuant is not anything like the dozen or so Minnesota businesses that have sought funding directly from small investors in

EIN Presswire: VivaQuant, Inc. Named Finalist for 2021 Tekne Awards

VivaQuant selected as a finalist for the Tekne Medical Technology innovation award for its unique wearable arrhythmia monitor.

VivaQuant Receives FDA 510k Clearance for its RX-1 Rhythm Express Arrhythmia Device

VivaQuant, a digital health company with powerful technology to accurately and efficiently identify and report cardiac arrhythmias, has received FDA

VivaQuant algorithm shows 6-fold reduction in risk classification error relative to FDA published results

This study demonstrates that fully automated continuous beat to beat measurements over 24 hours can be obtained using the Rhythm

Categories